» Articles » PMID: 20674732

Nanocrystals: Industrially Feasible Multifunctional Formulation Technology for Poorly Soluble Actives

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2010 Aug 3
PMID 20674732
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

Poor solubility of new drugs and their related low oral bioavailability and general delivery problems are becoming a major challenge. Nanocrystals being a kind of "universal" formulation approach for these molecules are reviewed in this paper regarding the industrial feasibility, i.e. industrially available production processes (bottom-up and top-down technologies), regulatory aspects and nanotoxicology. This article also includes second generation nanocrystals (<<100 nm) as smartCrystals. The status of products on the market and in clinical phases is presented. The different special features of nanocrystals, which are exploited in different products, are described (tablets, capsule, aqueous nanosuspension). The main focus is given for oral and intravenous products. However, the potential and delivery strategies for other administration routes are discussed, i.e. dermal and mucosal, ocular, pulmonary and targeted delivery (e.g. via differential protein adsorption to the brain). In addition, the potential of the nanocrystal technology for delivery of poorly soluble, non-pharmaceutical actives is highlighted, i.e. in cosmetics or nutraceuticals.

Citing Articles

Pharmaceutical technological trends containing flavonoids: a patent review.

Oliveira A, Santos A, Nascimento Junior J, Santana Junior C, Brito J, Dos Santos J Future Med Chem. 2025; 17(3):363-379.

PMID: 39835701 PMC: 11792795. DOI: 10.1080/17568919.2025.2453408.


Strategies to Enhance Nanocrystal Formulations for Overcoming Physiological Barriers Across Diverse Routes of Administration.

Yanamadala Y, Muthumula C, Khare S, Gokulan K Int J Nanomedicine. 2025; 20():367-402.

PMID: 39816376 PMC: 11733173. DOI: 10.2147/IJN.S494224.


Nanocrystals in Dermal Drug Delivery: A Breakthrough for Enhanced Skin Penetration and Targeted Skin Disorder Treatments.

Alnaim A Pharmaceutics. 2025; 16(12.

PMID: 39771540 PMC: 11676127. DOI: 10.3390/pharmaceutics16121561.


Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery.

Brito S, Baek M, Bin B Pharmaceutics. 2024; 16(11).

PMID: 39598527 PMC: 11597055. DOI: 10.3390/pharmaceutics16111403.


Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood-Cerebrospinal Fluid Barrier for Enhanced CNS Drug Delivery.

Madadi A, Sohn M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204177 PMC: 11357388. DOI: 10.3390/ph17081070.